Literature DB >> 9671429

Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow.

G L Zhan1, C B Toris, C B Camras, Y L Wang, M E Yablonski.   

Abstract

The mechanism of the ocular hypotensive effect of bunazosin hydrochloride (an alpha1-adrenergic antagonist) and the possible intermediary role of prostaglandins were studied in New Zealand albino rabbits. Aqueous flow, outflow facility and uveoscleral outflow were determined by fluorophotometry, and intraocular pressure (IOP) was measured by pneumatonometry on the fourth day of twice daily topical treatment with 0.1% bunazosin. Uveoscleral outflow was measured with a tracer infusion technique at 1 to 2 hours after one dose of 0.1% bunazosin. Total outflow facility was measured by a two-level constant-pressure infusion method before and at one hour after one dose of 0.1% bunazosin. The effect of topically applied cyclooxygenase inhibitors, including 0.25% indomethacin and 0.03% flurbiprofen, on the IOP reduction after bunazosin was evaluated. At 3 hours after the seventh consecutive dose given twice-daily, bunazosin significantly (P<0.001) reduced IOP to 13.4+/-0.8 mm Hg (mean +/- SEM) from a baseline of 19.6+/-1.1 mm Hg. Indomethacin significantly inhibited the IOP reduction after one dose of bunazosin, whereas flurbiprofen did not (repeated measures ANOVA). Bunazosin significantly increased uveoscleral outflow (P<0.05) and total outflow facility (P<0.02), but not fluorophotometric outflow facility or aqueous flow. It is concluded that, in rabbits, 0.1% bunazosin reduces IOP predominantly by increasing uveoscleral outflow. The role of prostaglandins in this effect is equivocal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671429     DOI: 10.1089/jop.1998.14.217

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  9 in total

1.  Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes.

Authors:  Fumiko Suzuki; Takanobu Taniguchi; Seigo Nakamura; Yoshio Akagi; Chikara Kubota; Makoto Satoh; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Correlation between the additive effect of bunazosin and the response to latanoprost on intraocular pressure in patients with glaucoma treated with bunazosin as adjunctive therapy to latanoprost.

Authors:  Hidetoshi Tsukamoto; Hidetaka Noma; Hiromu K Mishima
Journal:  Jpn J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.447

Review 3.  Unconventional aqueous humor outflow: A review.

Authors:  Mark Johnson; Jay W McLaren; Darryl R Overby
Journal:  Exp Eye Res       Date:  2016-02-02       Impact factor: 3.467

4.  The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.

Authors:  Takashi Ota; Makoto Aihara; Tadashiro Saeki; Shuh Narumiya; Makoto Araie
Journal:  Br J Ophthalmol       Date:  2006-11-23       Impact factor: 4.638

Review 5.  Anterior segment alterations and comparative aqueous humor proteomics in the buphthalmic rabbit (an American Ophthalmological Society thesis).

Authors:  Deepak P Edward; Rachida Bouhenni
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

6.  Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Authors:  Zhou Wan; David F Woodward; W Daniel Stamer
Journal:  Expert Rev Ophthalmol       Date:  2008

7.  Episcleral venous pressure responses to topical nitroprusside and N-Nitro-L-arginine methyl ester.

Authors:  David O Zamora; Jeffrey W Kiel
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

8.  Ocular pharmacokinetic/ pharmacodynamic modeling for bunazosin after instillation into rabbits.

Authors:  Koji Sakanaka; Kouichi Kawazu; Masahide Tomonari; Takashi Kitahara; Mikiro Nakashima; Shigeru Kawakami; Koyo Nishida; Junzo Nakamura; Hitoshi Sasaki
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

9.  Anterior segment optical coherence tomography changes with introduction and discontinuation of tamsulosin.

Authors:  Abdullah Al-Kharashi; Amir A Azimzadeh; Jerry Leung; Sidney Radomski; Lenny Radomski; Wai-Ching Lam
Journal:  Saudi J Ophthalmol       Date:  2016-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.